Industry News

Crescita Therapeutics Inc., a drug development company that owns topical products for use in the treatment of medical conditions related to dermatology and pain, today announced that it has acquired INTEGA Skin Sciences Inc., a Montreal-based dermatology company which develops, manufactures, sells and markets science-based quality skin care products."/>
Crescita Therapeutics™ Inc. Announces Acquisition of INTEGA Skin Sciences
Crescita Therapeutics Inc., a drug development company that owns topical products for use in the treatment of medical conditions related to dermatology and pain, today announced that it has acquired INTEGA Skin Sciences Inc., a Montreal-based dermatology company which develops, manufactures, sells and markets science-based quality skin care products."/>
Crescita Therapeutics™ Inc. Announces Acquisition of INTEGA Skin Sciences
Cerecor Inc., a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced it will be featured as a presenting company at the 23 rd Annual NewsMakers in the Biotech Industry Conference. The conference is being held on September 9, 2016, at the Millennium Broadway Hotel in New York City. Uli Hacksell, President and Chief Executive Officer of Cerecor, will..."/>
Cerecor to Present at 23rd Annual NewsMakers in the Biotech Industry Conference in New York City, September 9, 2016
Inovio Pharmaceuticals, Inc. today announced that the Company will present a corporate overview at the following upcoming conferences:. Citi 11th Annual Biotech Conference Mandarin Oriental, Boston, Thursday, September 8 th, 1 x1 meetings. 23 rd Annual Newsmakers in the Biotech Industry Millennium Broadway Hotel, New York, Friday, September 9 th, 11:00 am ET."/>
Inovio Pharmaceuticals to Present at Upcoming Investment Conferences
Apple has provoked a multitude of different reactions across the Atlantic. In Congress and on the presidential election trail there has been mild approval. No-one likes tax cheats and there is strong US political momentum aimed at repatriating the trillions of dollars of reserves that US companies have been accumulating in Bermuda and elsewhere to reinvest in the domestic economy."/>
Daily Mail, London, Alex Brummer column [Daily Mail, London]
Perrigo Company plc today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Epiduo ® Gel. Epiduo ® Gel is indicated for the treatment of acne vulgaris in patients 12 years of age and older."/>
Perrigo Announces Tentative FDA Approval For Generic Version Of Epiduo® Gel
St. Jude Medical AMPLATZER™ Amulet™ IDE trial, which will evaluate the safety and effectiveness of the company’ s AMPLATZER™ Amulet™ Left Atrial Appendage Occluder used to close the left atrial appendage..."/>
St. Jude Medical Launches Global Clinical Trial to Evaluate a New Therapy Option for Patients at an Increased Risk of Stroke Due to Atrial Fibrillation
Cerner client Sharp HealthCare, a leading health care provider in San Diego, has selected Cerner, a global leader in health care technology, to extend its electronic health record to Sharp Community Medical Group, one of two affiliated medical groups.. The PowerChart Ambulatory™ EHR will support more than 200 primary care and specialty physicians across Sharp’ s outpatient facilities and independent physician practices. Integration with the..."/>
Sharp HealthCare to Expand Cerner Digital Record
Evogene Ltd., a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries, today announced it will be featured as a presenting company at the 18 th Annual Rodman& Renshaw Global Investment Conference. The conference is being held on September 11-13, 2016, at Lotte New York Palace Hotel in New York City.. Ofer Haviv, Evogene President and Chief Executive Officer, will provide an overview of the..."/>
Evogene Announces Participation at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016
Aviragen Therapeutics, Inc., a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, September 8, 2016 at 4:30 p.m. ET to review the Company’ s financial results for the three month period and 2016 fiscal year ended June 30, 2016 and will provide an update on recent corporate developments. The Company will issue a press release summarizing its financial..."/>
Aviragen Therapeutics to Host Conference Call to Report Fourth Quarter and Fiscal Year 2016 Financial Results on September 8, 2016
RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that Mr. Adi Frish, RedHill’ s Senior VP Business Development& Licensing, will be presenting at the 9 th Annual BioPharm America International Partnering Conference, on Wednesday,..."/>
RedHill Biopharma to Present at the 9th Annual BioPharm America International Partnering Conference
Jaguar Animal Health, Inc., an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, announced additional topline results today from its study conducted in conjunction with researchers from Cornell University College of Veterinary Medicine to evaluate the efficacy of the prophylactic use of a second-generation, powder formulation of..."/>
Jaguar Animal Health Announces Additional Topline Results from Study of Second-Generation Formulation of Neonorm Calf Conducted in Association with Cornell University College of Veterinary Medicine
Amgen and Boehringer Ingelheim today announced that Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836908, a bispecific T cell engager that targets B-cell maturation antigen, a potential target for multiple myeloma. BI 836908 is currently in Phase 1 studies. BI 836908 was originally licensed to Boehringer Ingelheim by Micromet before the company was acquired..."/>
Amgen Obtains Global Development And Commercial Rights From Boehringer Ingelheim For Investigational BiTE® Immuno-Oncology Drug For Multiple Myeloma
Halozyme Therapeutics, Inc., an oncology biotech developing novel oncology and drug-delivery therapies, today named biotech veteran Mark J. Gergen as senior vice president and chief operating officer, reporting to Dr. Helen Torley, president and chief executive officer. Gergen will be responsible for corporate development, including the management of Halozyme's proprietary ENHANZE™ platform collaborations and overseeing the global..."/>
Halozyme Names Mark J. Gergen As Chief Operating Officer
CANTEL MEDICAL CORP. is pleased to announce that Seth M. Yellin has recently been promoted to Executive Vice President, Strategy and Corporate Development from Senior Vice President, Corporate Development. In his new role, Mr. Yellin will have responsibility for Cantel's strategic planning function along with his current role of corporate development, which includes leading the Company's active acquisition program."/>
Cantel Medical Promotes Seth M. Yellin to Executive Vice President
AstraZeneca has been forced to fork out pounds sterling 4.2 m to settle a bribery probe over allegations staff used gifts and cash to persuade doctors to buy its drugs. The Anglo-Swedish pharmaceutical giant is accused of setting up bogus conferences, organising false travel documents and creating fake tax receipts to' reward or influence' healthcare providers. The US markets watchdog claims staff at the firm made' numerous improper payments' to doctors in China and..."/>
It set up bogus conferences, supplied fake travel invoices and handed gifts to hospitals [Daily Mail, London]
OptimizeRx Corp., a health technology software company whose premier content-delivery platform enables pharmaceutical companies to provide on-demand patient-care services, has been invited to participate at the fourth annual CBI Coupon and Co-Pay Offer Design Optimization Conference on September 15-16, 2016. The conference will be held at the DoubleTree by Hilton in Philadelphia, PA.. OptimizeRx CEO William Febbo will participate in a..."/>
OptimizeRx Corporation to Participate at CBI’s 4th Annual Coupon and Co-Pay Offer Design Optimization Conference on September 16, 2016
SteadyMed Ltd., a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high value diseases with unmet parenteral delivery needs, today announced that it has completed the manufacture of all of the Trevyent ® batches for shelf-life studies needed to support the submission of its NDA in the first quarter of 2017.. “Trevyent, our lead drug product candidate in development for the treatment of..."/>
SteadyMed Announces Completion of Pre-NDA Submission Manufacturing Activities
Flex Pharma, Inc. today announced that it will present a corporate overview at the following upcoming investor conferences in September:. The BioCentury NewsMakers Conference on September 9, 2016 at 11:30 a.m. in New York, NY; The Rodman& Renshaw 18 th Annual Global Investment Conference on September 13, 2016 at 9:35 a.m. in New York, NY; The Mizuho Neuro-Focus Therapeutics Conference on September 21, 2016 in Boston, MA.. A live webcast of Flex Pharma’ s presentations at these..."/>
Flex Pharma Presenting at Upcoming Investor Conferences in September 2016
Collegium Pharmaceutical, Inc. today announced that it will present data on Xtampza ® ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, at PAINWeek 2016 on September 8 th in Las Vegas.. The following posters will be presented during the poster session on Thursday, September 8 th from 6:30 pm- 8:30 pm PT:. The poster titled,“ The Effect of Physical Manipulation by Crushing of Xtampza ® ER Compared with the..."/>
Collegium Announces Scientific Presentations at PAINWeek 2016 Meeting
Hemostemix Inc. thanks shareholders for their overwhelming support for their current experienced Board and reminds all shareholders to vote their WHITE proxy by 2:00 PM on September 6, 2016.. A group of self-interested Dissidents are attempting to ambush shareholders and take over Hemostemix' Board. The Dissidents have NO experience in developing drugs or medical devices, nor the knowledge and understanding to take Hemostemix' technology to..."/>
Hemostemix Inc. Reminds Shareholders to Vote the WHITE Proxy in Favour of the Current Trusted Board
Cytokinetics, Inc. today announced the advancement of omecamtiv mecarbil to Phase 3 clinical development with a cardiovascular outcomes clinical trial expected to initiate in the fourth quarter of 2016. Omecamtiv mecarbil, a novel investigational cardiac myosin activator, enhances cardiac function by increasing cardiac contractility and is being developed for the potential treatment of patients with chronic heart failure.."/>
Cytokinetics and Amgen to Advance Omecamtiv Mecarbil to Phase 3 Clinical Development

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology798 Articles
Consumer Discretionary691 Articles
Financials532 Articles
Health Care487 Articles
Industrials450 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at